QUARKBIO

Reproductive Genetics

MIRA™

miRNA-Based Endometrial Receptivity Analysis to Improve IVF Success

The optimal time for embryo transfer varies among individuals - 30% of infertility patients have a displaced window of implantation (WOI). MIRA™, the next generation endometrial receptivity analysis based on miRNAs and analyzed on the QuarkBio's NextAmp™ Analysis System, is intended to determine the status of a female's endometrial receptivity, ensuring the optimal embryo implantation time for personalized in vitro fertilization (IVF) treatment.

For Research Use Only

Key Features

LESS SAMPLE NEEDED

Able to detect lower sample amounts (0.15 ng/rxn), reducing the fail rate of the test

SHORT TURNAROUND TIME

Simpler and faster operation time, shortening the turnaround time of the analysis and providing a speedier sample to data workflow

HIGH REPRODUCIBILITY

Our quantitative amplification-based platform with higher reproducibility compared to NGS

DECENTRALIZATION

Easy-to-use, enabling decentralized labs to provide high quality service with consistency in numerous locations

Specifications

Properties	Specifications
Input Analyte Type	Nucleic acids (miRNA)
Input Amount	2 ng for cDNA synthesis; 0.15 ng/rxn for Analysis
Target(s) of Detection	~100 miRNA Biomarkers
Total Turnaround Time	3 Days
Compatible Instrument	NextAmp™ Analysis System (Q Station™ 1000 with PanelChip®)
Specimen Type(s)	Endometrial Tissue

Ordering Information

Reference No.	Product Name	Package Size
MRASS-01	MIRA™ Sample Submission Kit	1 Set
MIURTP-24-R (MIURTP-24-R1, MIURTP-24-R2)	microRNA Universal RT Kit Plus (Reagent Box 1 & Box 2)	24 Assays
MRA-24 (MRA-24-R1, MRA-24-R2, MRA-24-C)	MIRA™ Assay Kit (Reagent Box 1, Box 2, & MIRA™ PanelChip®)	24 Assays

For more information, please contact: info@quarkbiosciences.com